Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops.
OBJECTIVE
To examine central corneal mechanical sensitivity (CCMS) after the instillation of latanoprost, travoprost, and bimatoprost.


METHODS
Nonrandomized interventional study.


METHODS
Latanoprost was used in 24 patients (43 eyes), travoprost in 21 patients (42 eyes), and bimatoprost in 15 patients (28 eyes). CCMS was examined with the Cochet-Bonnet esthesiometer before the instillation of prostaglandin analogs and then 5 and 30 minutes later. Examination of Schirmer and breakup time (BUT) tests were also performed. Thirty healthy subjects were examined as a control group.


RESULTS
CCMS was significantly reduced at the 5-minute interval for latanoprost (P = .03), travoprost (P = .04), and bimatoprost (P = .04). Differences between the three analogs were statistically not significant. CCMS changes significantly correlated with Schirmer and BUT test scores.


CONCLUSIONS
The correlation between CCMS reduction and BUT and Schirmer test scores implies that the use of artificial tears may be considered if prostaglandin analogs are administered.
Kozobolis
Vassilios P
VP
Department of Ophthalmology, Democritus University of Thrace, Thrace, Greece.
Detorakis
Efstathios T
ET
Maskaleris
George
G
Koukoula
Stavroula C
SC
Fountoulakis
Nikitas
N
Chrysochoou
Fotios
F
Konstas
Anastasios G
AG
D000368:Aged; D000369:Aged, 80 and over; D000577:Amides; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D003315:Cornea / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008055:Lipids / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000009:adverse effects; D012677:Sensation / Q000187:drug effects* / Q000502:physiology; D012678:Sensation Disorders / Q000139:chemically induced* / Q000503:physiopathology; D000069557:Travoprost
D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost